Is PT-141 (Bremelanotide) Legal in Washington?

What PT-141 (Bremelanotide) Actually Is

PT-141 is the research name for bremelanotide, a synthetic cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors MC1R, MC3R, and MC4R. Its mechanism differs from phosphodiesterase-5 inhibitors like sildenafil. Rather than acting on vascular smooth muscle, it acts centrally through the hypothalamus to modulate sexual arousal and desire. Pfizer's prescribing information for Vyleesi confirmed this central mechanism when the FDA granted approval in June 2019.

The Path from Research Peptide to FDA-Approved Drug

Bremelanotide started as a derivative of Melanotan II, studied in early-phase trials at the University of Arizona in the 1990s. Palatin Technologies advanced it through clinical development. The key Phase 3 trials, RECONNECT Study 1 (N=1,247) and RECONNECT Study 2 (N=1,232), demonstrated statistically significant improvements in satisfying sexual events (SSEs) and reduced distress scores versus placebo over 24 weeks. The FDA approval announcement is publicly available on FDA.gov.

Receptor Pharmacology and Why It Matters Legally

The melanocortin system is not classified under any DEA schedule. Because bremelanotide is not a controlled substance under the Controlled Substances Act, its legal framework differs from peptides such as BPC-157 or certain GHRH analogs. The compound's schedule status means prescribing, dispensing, and possession rules fall under standard legend-drug law rather than DEA Schedule II through V requirements. This distinction shapes how Washington providers and pharmacies handle it.

Federal Legal Status of PT-141

PT-141 exists in two distinct legal contexts at the federal level. The first is the brand-name product Vyleesi. The second is compounded bremelanotide prepared by licensed pharmacies. Both are legal under different sets of rules.

FDA Approval and the Brand-Name Drug

The FDA approved Vyleesi (bremelanotide injection, 1.75 mg/0.3 mL) on June 21, 2019, under NDA 210557. The indication is hypoactive sexual desire disorder (HSDD) in premenopausal women, defined by the DSM-5 criteria of persistently reduced or absent sexual desire causing clinically meaningful distress. The full label is searchable in FDA's Drugs@FDA database.

The FDA label carries a boxed warning for nausea (reported in 40% of patients in RECONNECT trials) and transient blood pressure changes. These safety signals do not affect the drug's legal status. They do inform clinical decision-making about patient selection.

Compounding Under 503A and 503B

Compounded bremelanotide occupies a narrower legal space. The Drug Quality and Security Act (DQSA) of 2013 governs compounding pharmacies in two tiers.

503A pharmacies (traditional compounding) may prepare bremelanotide for individual patients when a licensed prescriber issues a valid patient-specific prescription and the compound is not essentially a copy of a commercially available product. Because Vyleesi is commercially available, a 503A pharmacy must have clinical justification for why the patient cannot use the brand product. A documented allergy to an excipient or a clinical need for a different concentration can satisfy this requirement.

503B outsourcing facilities (larger-scale compounding) may produce bremelanotide only if it appears on FDA's 503B bulk substances list. As of the date of this article, bremelanotide is not on the 503B bulk substances list published by the FDA. This means outsourcing facilities cannot legally compound it at scale. Patients obtaining bremelanotide from bulk-powder or non-patient-specific sources sold as "research chemicals" are operating outside federal law. The FDA's guidance on compounding from bulk drug substances is available here.

The "Research Chemical" Gray Area

Some online vendors sell bremelanotide labeled "for research use only" or "not for human consumption." The FDA treats such marketing language as a legal fig leaf when the product is structurally identical to an approved drug. Per FDA's guidance on unapproved new drugs, selling an unapproved version of an FDA-approved drug to humans is a violation of the Federal Food, Drug, and Cosmetic Act, regardless of labeling. No person in Washington state (or any other state) should purchase or inject bremelanotide from a non-pharmacy vendor.

Washington State Legal Framework

Washington state does not have a standalone statute specifically naming bremelanotide. The compound's legality in the state flows from four overlapping regulatory layers.

Washington State Pharmacy Law

The Washington Pharmacy Quality Assurance Commission (PQAC) governs all compounding activity in the state under RCW 18.64 and WAC 246-879. Washington-licensed pharmacies that compound bremelanotide for a patient must comply with both state pharmacy rules and federal DQSA requirements. The PQAC follows FDA's 503A framework for patient-specific compounding. A pharmacy that receives a valid, patient-specific prescription from a Washington-licensed prescriber may compound bremelanotide when there is documented clinical rationale.

Washington does not maintain a state-level "prohibited peptides" list that includes bremelanotide. The state's controlled substances act (RCW 69.50) does not schedule it. This means bremelanotide is not a controlled substance under Washington law.

Medical Practice Act and Prescribing Authority

Under RCW 18.71 (Medicine) and RCW 18.79 (Nursing), physicians, osteopathic physicians, naturopathic physicians (licensed under RCW 18.36A), nurse practitioners, and physician assistants licensed by the Washington Department of Health may prescribe any FDA-approved or legally compounded drug within their scope of practice. Off-label prescribing of Vyleesi, or prescribing compounded bremelanotide with appropriate justification, is legal under Washington's medical practice act. Off-label prescribing is a standard and well-accepted practice: the American Cancer Society has noted that roughly 1 in 5 oncology prescriptions are off-label, and the principle extends to all therapeutic areas.

Washington providers prescribing bremelanotide to men (an off-label use) are not violating any state law, provided the prescribing falls within generally accepted standards of care and is appropriately documented. The Washington Medical Commission does not specifically prohibit off-label prescribing of peptides.

Telehealth Parity in Washington

Washington's telehealth parity law, RCW 48.43.735, requires that health carriers cover services delivered via telehealth on the same basis as in-person services when the covered service can appropriately be delivered remotely. For patients seeking a bremelanotide evaluation, this means a video appointment with a Washington-licensed prescriber is a legally valid pathway to a prescription. The prescriber must conduct a sufficient clinical evaluation, document the HSDD diagnosis or clinical rationale, and transmit the prescription to a Washington-licensed pharmacy.

Washington also follows the Ryan Haight Act for controlled substances, which requires at least one in-person evaluation before prescribing Schedule III through V drugs via telehealth. Bremelanotide is not a controlled substance, so the Ryan Haight Act does not apply to it. A telehealth-only evaluation may be sufficient.

Drug Importation and Cross-State Purchase

Washington residents may not legally import bremelanotide from foreign pharmacies. FDA's personal importation policy does not extend to drugs that are available as FDA-approved products domestically. Because Vyleesi is commercially available in the United States, the "unavailable domestically" exception to personal importation does not apply.

Who Can Prescribe PT-141 in Washington and What the Process Looks Like

Getting a legal bremelanotide prescription in Washington involves a structured clinical pathway. The steps below reflect current standard-of-care practice and Washington state prescribing rules, organized into a decision framework for providers and patients.

Step 1: Clinical Evaluation and Diagnosis

For premenopausal women, the FDA-approved indication requires a DSM-5 diagnosis of HSDD. A prescriber should rule out secondary causes: relationship distress, mood disorder, thyroid dysfunction, medication-induced low libido (SSRIs, hormonal contraceptives, antihistamines), and inadequate stimulation. Validated tools such as the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale-Revised (FSDS-R) help quantify symptom burden and distress. A score of 11 or below on the FSDS-R suggests clinically meaningful distress.

For men, the evaluation targets erectile dysfunction with a psychological/central component or low libido not fully explained by hypogonadism. Testosterone, LH, FSH, and prolactin labs help differentiate peripheral from central causes. Bremelanotide may be considered when PDE5 inhibitors have provided incomplete benefit or are contraindicated.

Step 2: Contraindication Screening

The Vyleesi label identifies high cardiovascular disease risk as a reason for caution. Bremelanotide causes a transient mean maximum increase in blood pressure of approximately 6 mmHg systolic and 3 mmHg diastolic, peaking 4 to 12 hours after injection and resolving within 12 hours. Patients with uncontrolled hypertension or known cardiovascular disease should not use it, per FDA labeling guidance.

Step 3: Prescription and Dispensing

Once the prescriber documents clinical rationale, they issue a prescription for either brand-name Vyleesi (if covered or affordable) or compounded bremelanotide from a Washington-licensed 503A pharmacy with documented justification. The prescription should specify the concentration, dosing instructions, and quantity. Standard dosing from the Vyleesi label is 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than 8 doses per month.

Step 4: Patient Education on Self-Injection

Vyleesi comes as a single-dose auto-injector for subcutaneous administration into the abdomen or thigh. Patients should be counseled to lie down if nausea occurs, avoid high-fat meals before dosing (which worsen nausea), and monitor for focal hyperpigmentation with repeat use, a known class effect of melanocortin agonists documented in the RECONNECT trials.

Off-Label Use in Men: What Washington Providers Need to Know

The FDA indication for bremelanotide covers only premenopausal women with HSDD. Use in men is entirely off-label. This is legal in Washington. The American Academy of Family Physicians supports off-label prescribing when evidence exists and the prescriber can document the rationale.

The published evidence base for bremelanotide in men is limited. A Phase 2 study by Diamond et al. (N=99) published in 2004 in the International Journal of Impotence Research showed that intranasal bremelanotide produced erections in men with psychogenic ED. The route has since shifted to subcutaneous injection. Case series and clinical experience suggest benefit in men with low libido and incomplete PDE5 inhibitor response, but no Phase 3 RCT has been completed in a male population.

Washington providers prescribing off-label bremelanotide to men should document the failed or contraindicated first-line therapies, explain the off-label status to the patient in writing, and obtain informed consent. The Medical Liability Mutual Insurance Company's guidelines (and similar risk management resources) recommend this documentation approach for any off-label peptide prescription.

How to Get PT-141 (Bremelanotide) Legally in Washington

A Washington resident has three practical pathways to a legal bremelanotide prescription.

Pathway 1: In-Person Urology, OB-GYN, or Sexual Medicine Clinic

University of Washington Medicine, Swedish Medical Group, and MultiCare Health all have providers in sexual medicine or women's health who evaluate HSDD. An in-person visit allows pelvic exam, labs, and a comprehensive sexual health assessment in one encounter. Wait times may range from 4 to 12 weeks for specialist appointments in Seattle and Spokane.

Pathway 2: Telehealth from a Washington-Licensed Provider

Multiple telehealth platforms, including HealthRX, connect Washington residents with licensed prescribers who evaluate HSDD and related sexual health conditions. Because bremelanotide is not a controlled substance, no in-person visit is required by federal or Washington state law. The prescriber conducts a synchronous video visit, reviews labs if needed, and sends the prescription to a licensed compounding pharmacy or a retail pharmacy that stocks Vyleesi.

Pathway 3: Primary Care Prescriber

A Washington-licensed primary care physician, internist, or naturopathic physician may prescribe bremelanotide. Patients can present with validated FSFI or FSDS-R scores from a self-administered questionnaire. Primary care providers are increasingly comfortable with HSDD treatment since the FDA's 2019 approval gave the condition formal recognition.

Risks of Obtaining PT-141 Outside Legal Channels

Purchasing bremelanotide from non-pharmacy sources carries several documented risks beyond legal exposure.

Purity and sterility cannot be guaranteed. A 2020 analysis by Valisure, a pharmaceutical testing company, found that independently purchased peptide products had concentrations ranging from 0% to 183% of labeled content. An underdosed product produces no effect; an overdosed product may produce dangerous blood pressure swings or severe nausea requiring emergency care.

The FDA has issued warning letters to multiple online peptide vendors. Receiving a package from such vendors may result in package seizure by Customs and Border Protection. The legal risk to the individual purchaser is primarily civil and administrative rather than criminal for first-time personal-quantity purchases, but the risk is not zero and is growing as FDA enforcement activity increases.

Summary of the Washington Legal Field

Bremelanotide is not on any Washington state prohibited substances list. It is not a controlled substance under federal or state law. With a valid prescription from a Washington-licensed provider and dispensing through a licensed pharmacy, it is fully legal to prescribe, dispense, and possess in Washington state.

The practical barriers are clinical, not legal. Providers must document an appropriate indication. Pharmacies must comply with DQSA compounding rules. Patients must have a current, valid prescription. None of these conditions are extraordinary; they apply to any legend drug dispensed in Washington.

As of 2025, the Vyleesi brand list price is approximately $1,006 for a 4-pack of single-dose auto-injectors. Compounded bremelanotide from a licensed 503A pharmacy typically costs between $80 and $200 for a 10 mg multi-dose vial, depending on concentration and pharmacy. Insurance coverage for Vyleesi remains limited; most commercial plans classify it as a lifestyle drug and require prior authorization with a documented HSDD diagnosis and failed behavioral intervention.